Zacks Investment Research
01 Jul 2026, 15:45 UTC · 1h ago
Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
01 Jul 2026, 15:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Collegium Pharmaceutical raised its 2026 product revenue guidance to a range of $865-$895 million from the previous $805-$825 million. — A significant upward revision in revenue guidance typically acts as a strong positive catalyst for share price.
+0.60The company completed the acquisition of Azstarys from Corium Therapeutics, which is expected to be immediately accretive to earnings. — Immediate earnings accretion from an acquisition improves the bottom line and expands the company's market position.
+0.50Jornay PM sales increased 36% year over year in Q1 2026, with prescriptions rising 14% to over 206,000. — Strong growth in a core product franchise validates the company's commercial execution and growth trajectory.
+0.40Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
